IP Library Granted Patent US 10,668,285
Granted Patent B2
US 10,668,285 · App. 13/294,875 · Granted Jun 2, 2020

Systems and methods to place one or more leads in tissue to electrically stimulate nerves to treat pain

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,668,285
App. No.
13/294,875
Granted
Jun 2, 2020
Kind
B2
Abstract

It has been discovered that pain felt in a given region of the body can be treated, not by motor point stimulation of muscle in the local region where pain is felt, but by stimulating muscle spaced from a “nerve of passage” in a region that is superior (i.e., cranial or upstream toward the spinal column) to the region where pain is felt. Spinal nerves such as the intercostal nerves or nerves passing through a nerve plexus, which comprise trunks that divide by divisions and/or cords into branches, comprise “nerves of passage.”

Claims (43)

1. A method to reduce and/or relieve pain perceived by a patient, the method comprising the steps of:

percutaneously inserting an open-core coiled fine wire lead having a single monopolar electrode into a body of the patient outside a spinal column in a first region having muscle tissue and a spinal nerve that is between a painful region and a center of the body of the patient;

placing an external pulse generator away from the spinal nerve and outside of the painful region; and

stimulating the spinal nerve to recruit target fibers in the spinal nerve while minimizing recruitment of non-target fibers in the spinal nerve, wherein the electrode is within electrical proximity to and physically spaced from the spinal nerve.

2. A method according to claim 1 wherein the electrode is spaced from the spinal nerve by a distance of between about one millimeter to about fifty millimeters.

3. A method according to claim 1 , wherein the spinal nerve includes a nerve trunk.

4. A method according to claim 3 , wherein the monopolar electrode is generally on a plane with the nerve trunk and spaced a distance from the nerve trunk.

5. A method according to claim 4 , wherein the distance is greater than two millimeters.

6. A method according to claim 4 , wherein the distance is between about two to fifty millimeters.

7. A method according to claim 3 , wherein the monopolar electrode is spaced in a direction projecting out from a center of the nerve trunk and generally perpendicular to a longitudinal axis of the nerve trunk.

8. A method according to claim 1 , wherein the single monopolar electrode is operatively attached with the lead at a distal end, whereby the lead encourages tissue in-growth to retain the lead in an operative position without inhibiting removal of the lead at a conclusion of the stimulation.

9. A method according to claim 1 , wherein the lead is configured to be stabilized during the stimulating while permitting withdrawal at conclusion of the stimulating.

10. A method to alleviate pain comprising:

identifying a tissue region that comprises skeletal muscle that is innervated by a spinal nerve, the spinal nerve also innervating a painful region perceived by a patient, wherein the tissue region is distant from the painful region,

percutaneously placing an open-core coiled fine wire lead having a monopolar electrode at a distal portion of the lead within the tissue region and spaced from the spinal nerve, whereby the monopolar electrode is between the painful region and a spinal cord of the patient, and

applying stimulation to the monopolar electrode through an external pulse generator according to predefined therapeutic stimulation parameters to provide therapeutic nerve stimulation to recruit target fibers in the spinal nerve while minimizing recruitment of non-target fibers in the spinal nerve to alleviate pain in the painful region without functional nerve stimulation at a motor point.

11. A method according to claim 10 wherein the spinal nerve includes a nerve passing through a nerve plexus.

12. A method according to claim 10 wherein the spinal nerve includes a brachial plexus, a lumbar plexus, a sacral plexus, and a cervical plexus.

13. A method according to claim 10 wherein the spinal nerve includes at least one of a femoral nerve, a sciatic nerve and an intercostal nerve.

14. A method according to claim 10 wherein the electrode is spaced from the spinal nerve by a distance of between about one millimeter to about fifty millimeters.

15. A method according to claim 10 , wherein the spinal nerve comprises a nerve trunk and the monopolar electrode is spaced a predetermined distance from the nerve trunk.

16. A method according to claim 10 , wherein the monopolar electrode is placed within the tissue region by percutaneously inserting the monopolar electrode within the tissue region.

17. A method according to claim 10 , wherein the alleviation of pain is non-narcotic.

18. A method according to claim 10 , wherein placing the lead having the monopolar electrode further includes guiding the monopolar electrode via ultrasound within the tissue region spaced from the spinal nerve by at least two millimeters and in electrical proximity to the spinal nerve.

19. A method according to claim 10 , wherein placing the lead having the monopolar electrode includes inserting an introducer needle into the tissue region and anchoring the monopolar electrode with the tissue region distant to the, painful region and spaced from the spinal nerve.

20. A system for reducing and/or relieving pain in a painful region comprising:

a percutaneous open-core coiled fine wire lead having a monopolar electrode, and

an external stimulating device operatively coupled with the percutaneous open-core coiled fine wire lead to apply stimulation to a spinal nerve innervating a painful region perceived by a patient with the monopolar electrode inserted into muscle tissue that is: i) distant to the painful region, ii) spaced from the spinal nerve to recruit target fibers in the spinal nerve while minimizing recruitment of non-target fibers in the spinal nerve, and iii) between the painful region and a center of a body of a patient.

21. A system according to claim 20 , wherein the intramuscular lead is configured to withstand mechanical forces and resist migration.

22. A system according to claim 20 , wherein the intramuscular lead includes a coiled wire electrode lead configured to resist migration in the periphery away from the center of the body.

23. A system according to claim 20 , wherein the percutaneous lead includes at least one coiled metal wire positioned within a generally flexible elastomer core.

24. A system according to claim 20 , wherein the percutaneous lead includes at least one coiled metal wire having an insulation positioned on an exterior thereof.

25. A system according to claim 24 , wherein the insulation includes a biocompatible polymer film.

26. A system according to claim 25 , wherein the biocompatible polymer film includes at least one of polyfluorocarbon, polymide and parylene.

27. A system according to claim 20 , wherein the percutaneous lead includes a coating with a textured bacteriostatic material.

28. A system according to claim 20 , wherein the percutaneous lead is configured to discourage in-growth of connective tissue over a portion of its length.

29. A system according to claim 28 , wherein a distal end of the percutaneous lead is configured to encourage in-growth of connective tissue.

30. A system according to claim 20 , wherein the percutaneous lead includes an anchoring element.

31. A system according to claim 30 , wherein the anchoring element generally resists dislodgement and migration out of a predetermined operative position in the muscle tissue.

32. A system to alleviate pain perceived by a patient in a painful region, the system comprising:

a percutaneous open-core coiled fine wire lead having a monopolar electrode, wherein the percutaneous open-core coiled fine wire lead is configured to withstand mechanical forces in flexible peripheral regions of a body of a patient, and the monopolar electrode is placed outside of the spinal column and within a peripheral tissue region that comprises skeletal muscle and a spinal nerve, wherein the tissue region is between the painful region and a center of the body of the patient, the tissue region is distant to the painful region and wherein the monopolar electrode is spaced from the spinal nerve, and

an external electrical pulse generator operatively coupled with the lead applying stimulation to the monopolar electrode according to predefined therapeutic stimulation parameters to provide therapeutic nerve stimulation to recruit target fibers in the spinal nerve while minimizing recruitment of non-target fibers in the spinal nerve to alleviate pain in the painful region without functional nerve stimulation at a motor point.

33. A method according to claim 32 , wherein the spinal nerve includes a nerve trunk and the at least one electrode is spaced a predetermined distance from the nerve trunk.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Feb 8, 2024
From: THE DIRECTOR OF DEVELOPMENT, STATE OF OHIO, FORMERLY KNOWN AS THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
To: SPR THERAPEUTICS, INC., FORMERLY KNOWN AS SPR THERAPEUTICS, LLC
Reel/Frame 066415/0750 →
RELEASE OF SECURITY INTEREST Recorded Feb 8, 2024
From: THE DIRECTOR OF DEVELOPMENT, STATE OF OHIO, FORMERLY KNOWN AS THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
To: SPR THERAPEUTICS, INC., FORMERLY KNOWN AS SPR THERAPEUTICS, LLC
Reel/Frame 066526/0025 →
SECURITY INTEREST Recorded Jan 30, 2024
From: SPR THERAPEUTICS, INC.
To: GEMINO HEALTHCARE FINANCE, LLC
Reel/Frame 066412/0400 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 30, 2024
From: SPR THERAPEUTICS, INC.
To: SLR INVESTMENT CORP., AS AGENT
Reel/Frame 066381/0075 →
RELEASE OF SECURITY INTEREST Recorded Oct 15, 2019
From: THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
To: SPR THERAPEUTICS, INC.
Reel/Frame 050728/0721 →
RELEASE OF SECURITY INTEREST Recorded Oct 15, 2019
From: THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
To: SPR THERAPEUTICS, INC.
Reel/Frame 050728/0676 →
CHANGE OF NAME Recorded Dec 6, 2017
From: SPR THERAPEUTICS, LLC
To: SPR THERAPEUTICS, INC.
Reel/Frame 044716/0812 →
SECURITY INTEREST Recorded Nov 9, 2017
From: SPR THERAPEUTICS, INC.
To: THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
Reel/Frame 044414/0575 →
SECURITY INTEREST Recorded Nov 9, 2017
From: SPR THERAPEUTICS, INC.
To: THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
Reel/Frame 044715/0395 →
SECURITY INTEREST Recorded Sep 24, 2014
From: SPR THERAPEUTICS, LLC
To: OHIO DEVELOPMENT SERVICES AGENCY
Reel/Frame 033809/0771 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2013
From: NDI MEDICAL, LLC
To: SPR THERAPEUTICS LLC
Reel/Frame 031816/0488 →